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Abstract

Objective: The aim of this study was to examine the effects of anesthetic agents used
as premedication in patients undergoing electroconvulsive therapy (ECT) for diagnoses of
bipolar disorder or major depression in terms of convulsion, recovery period, and
hemodynamic parameters.
Materials and Method: This retrospective study was carried out by screening the
anesthesia forms of patients in a psychiatry clinic in Turkey.
Results: Researchers reviewed 104 patient files, of which 39 fit the inclusion criteria.
26 patients were given premedication; 13 patients were not given premedication. The study
found a significant difference between the group to which dexmedetomidine was given
and the non-premedication group in terms of mean arterial blood pressure and heart rate.
A significant difference was also found between the group to which midazolam was given
and the non-premedication group in terms of peripheral oxygen saturation.
Conclusion: Premedication before ECT may be used to reduce the side effects after
ECT without affecting convulsions and the recovery period.
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✓ Premedication may prevent hemodynamic responses that may occur as a response to this
therapy. It also prevents the occurrence of side effects.
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Introduction
Intravenous anesthetic agents such as short-acting
midazolam and propofol are widely used to provide
anesthesia in ECT applications (1). Ideal hypnotic
medications used in ECT as anesthetics should have short
half-lives, should not affect the onset/attack period and the
quality, and should not disturb the hemodynamic balance.
However, these anesthetic medications used for induction
shorten the convulsion period and lengthen the recovery
period, and also cause changes in hemodynamic
parameters (2, 3).
Constituting sufficient convulsion for an effective ECT
enables the occurrence of the desired therapeutic effect.
The motor attack period should continue for approximately
20-30 seconds to achieve a successful clinical result. If the
attack period is shorter than 15 seconds or longer than 120
seconds, the ECT will be ineffective. One of the factors
affecting this result is the anesthetic medication used.
These medications may shorten the attack period by
increasing the attack threshold based on the medication
dose (2, 3).
Although there have been no notifications about side
effect occurrence in patients to whom ECT has been
applied when dexmedetomidine and midazolam have been
given, the number of studies examining these two sedative
medications is low. A study by Mızrak et al. (4) indicated
that low-dose dexmedetomidine given as premedication
may be a beneficial alternative to midazolam. Several
studies have reported that dexmedetomidine increases the
attack period, while others have reported no effect on the
attack period (5, 6). Various studies have shown that
midazolam, which is an anticonvulsive agent in the
benzodiazepine group and which decreases the
hemodynamic response, prominently increases the attack
period when used in ECT induction. However, studies that
demonstrate an effect of midazolam applied in low doses
as premedication on the attack period have been lacking (3,
7).
This study assessed the effects of anesthetic agents used
as premedication for patients undergoing ECT for
diagnoses of bipolar disorder or major depression in terms
of convulsion, recovery period, and hemodynamic
parameters.

Materials and Methods

committee (Decision No: 2725, Meeting Date: June 6,
2012) and from the institution were obtained. The
researchers reviewed the follow-up forms of 18-65-yearold patients who were categorized as physical status 1 and
2 by the American Society of Anesthesiologists (ASA),
who were diagnosed with bipolar disorder or major
depression, and who underwent three sessions of ECT.
Patients with ischemic heart disease, arrhythmia,
hypertension, or epilepsy, or who were pregnant, used beta
blockers, or were allergic to any medications, were not
included in the study.
The population considered for the study consisted of
104 patients to whom ECT was given within a six-month
period. Of these, 39 fit the inclusion criteria and thus were
included. 26 patients had been given either
dexmedetomidine (n = 13) or midazolam (n = 13), and no
premedication occurred in another 13. In terms of
premedication, 0.025 mg/kg IV midazolam or 0.5 μg/kg IV
dexmedetomidine were administered by infusion. For the
general anesthesia, a 4 mg/kg dose of thiopental and a 1
mg/kg dose of succinylcholine were administered
intravenously to all patients regardless of whether
dexmedetomidine, midazolam, or no premedication had
been previously administered.
Researchers used a sub-structured questionnaire in
which features related to descriptive characteristics, ECT
side effects, and hemodynamic parameters of participants
were recorded.
o Questionnaire

related

to

the

descriptive

characteristics of participants: This questionnaire
included questions about the age, sex, height, weight,
and the diagnosis of participants.
o Questionnaire related to ECT side effects and
hemodynamic
parameters:
Data
for
this
questionnaire were obtained from patient files and were
related to (1) the current amount given (in joules), (2)
the mean arterial blood pressure (MAP), (3) heart rate
(HR) and peripheral oxygen saturation (SpO2) values,
(4) the recovery period, (4) the convulsion period, and
(5) the side effects that occurred.
Data were analyzed using the Statistical Package for
Social Sciences (SPSS Inc., Chicago, IL., USA) 15.0
program. The mean ± standard deviation and frequency

This study was carried out at the psychiatry service of
a training and research hospital by reviewing the files of

analysis were used for descriptive statistics. The KruskalWallis test was used for inter-group comparisons of
continuous variables. Bonferroni corrections for Mann-

patients to whom ECT was applied within a six-month
period after the necessary approvals from the local ethical

Whitney U tests were used for advanced binary
comparisons. Significant p values were set at < 0.05.
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Results

in Group II as premedication, and no premedication was
used in 13 patients in Group III.
No statistically significant difference between the
groups were found in terms of age, height, weight, sex, or
disease diagnosis.

Table 1 presents the descriptive characteristics of the
participants.
The study found that dexmedetomidine was used in 13
patients in Group I, and midazolam was used in 13 patients

Table 1. Comparison of the descriptive characteristics of the participants

Group I

Group II

Group III

(n = 13)

(n = 13)

(n = 13)

Features

p
(Mean ± SD) /

(Mean ± SD) /

(Mean ± SD) /

n (%)

n (%)

n (%)

Age (year)

32.6 ± 5.6

31.0 ± 9.7

29.8 ± 8.9

0.792

Body Height
(cm)

172 ± 7.2

171.3 ± 10.1

170.6 ± 10.4

0.978

Body Weight
(kg)

75.4 ± 15.5

74.6 ± 12.1

71.8 ± 11.9

0.628

Female

4 (30.8)

2 (15.4)

3 (23.1)

0.648

Male

9 (69.2)

11 (84.6)

10 (76.9)

Depression

4 (30.8)

6 (46.2)

3 (23.1)

Bipolar

9 (69.2)

7 (53.8)

10 (76.9)

Sex

Diagnosis
0.446

Group I: Patients given dexmedetomidine premedication. Group II: Patients given midazolam premedication.
Group III: Patients given no premedication.

Table 2 presents group comparisons of hemodynamic
parameters, convulsion, and recovery periods. A
statistically significant difference was found between the
5th, 10th, and 15th minute after ECT in terms of MAP;
between the 5th and 10th minute after ECT in terms of HR;
and at the 10th minute after the premedication was given

in terms of SpO2 value. Further analysis found that the
difference between MAP and HR occurs across Groups I
and III (p < 0.017), and the difference in SpO2 occurs
across Groups II and III (p = 0.008). No statistically
significant difference was found between groups in terms
of recovery and convulsion periods (p > 0.05).

Table 2. Comparison of patients in terms of hemodynamic parameters, convulsion, and recovery period
Group I

Group II

(Mean ±
SD)

(Mean ±
SD)

(Mean ± SD)

T0

91.1 ± 8.3

95.3 ± 9.8

92.8 ± 10.3

0.621

T1

85.0 ± 8.9

90.1 ± 8.0

90.0 ± 10.1

0.277

T2

83.4 ± 7.2

87.5 ± 8.2

88.0 ± 8.5

0.293

Features

MAP (mmHg)

Group III
p
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T3

102 ± 17.7

102.9 ± 9.7

112.0 ± 10.7

0.045*

T4

90.6 ± 9.8

98.5 ± 10.8

104.0 ± 11.0

0.018*

T5

88.8 ± 8.6

96.3 ± 9.9

99.0 ± 9.7

0.031*

T0

80.9 ± 7.5

86.0 ± 10.1

84.0 ± 14.1

0.344

T1

75.5 ± 11.0

85.6 ± 10.3

83.4 ± 12.9

0.092

T2

73.0 ± 9.5

81.1 ± 11.4

82.3 ± 13.3

0.096

T3

85.9 ± 11.2

98.6 ± 12.9

99.1 ± 11.8

0.019*

T4

84.7 ± 10.4

95.1 ± 10.2

99.3 ± 9.4

0.004*

T5

85.5 ± 9.8

94.3 ± 12.7

94.6 ± 10.9

0.058

T0

97.4 ± 1.7

97.3 ± 0.7

97.8 ± 1.3

0.620

T1

96.9 ± 1.5

96.3 ± 1.8

97.7 ± 1.5

0.093

T2

96.8 ± 1.5

95.8 ± 1.5

97.6 ± 1.4

0.028*

T3

95.6 ± 2.6

96.0 ± 2.3

96.8 ± 2.6

0.475

T4

94.5 ± 1.3

94.6 ± 1.5

94.6 ± 1.8

0.932

T5

94.6 ± 1.7

94.9 ± 1.4

94.6 ± 1.8

0.514

Convulsion period
(min)

19.2 ± 9.5

18.7 ± 6.6

24.8 ± 11.1

0.288

Recovery period (min)

14.4 ± 5.3

12.9 ± 8.1

10.8 ± 4.8

0.156

HR (min)

SpO2 (%)

Group I - Patients given dexmedetomidine, Group II – Patients given midazolam, Group III - Patients
given no premedication, T0 – The time before the premedication was administered to the patient, T1 - The
5th minute after the premedication was administered to the patient, T2 - The 10th minute after the
premedication was administered to the patient, right before induction, T3 - The 5th minute after ECT, T4
- The 10th minute after ECT, T5 - The 15th minute after ECT, MAP – Mean arterial pressure, HR – Heart
rate, SpO2 - peripheral oxygen saturation
*p<0.050
Table 3 shows the side effects noticed in the patients.
The patients in Groups I, II, and III showed two, three, and
five side effects, respectively. The most frequent side

effects were tearing in Groups I and II and coughing in
Group III.

Table 3. Side effects noticed in patients
Group I

Group II

Group
III

Total

n (%)

n (%)

n (%)

n (%)

Tearing

2 (15.4)

6 (37.5)

5 (27.7)

13 (27.7)

Coughing

1 (7.7)

2 (12.0)

9 (50.0)

12 (25.5)

Side effect
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Urinary incontinence

-

-

2 (11.1)

2 (4.3)

Postictal delirium

-

-

1 (6.3)

1 (2.1)

Shivering

-

-

1 (5.6)

1 (2.1)

Sweating

-

-

1 (5.6)

1 (2.1)

Total*

3

8

19

30

*n was folded.
Group I - Patients given dexmedetomidine, Group II - Patients given midazola, Group III - Patients given
no premedication.

Discussions
This study found a statistically significant difference
between the dexmedetomidine group and the no
premedication group in terms of MAP and HR. The
incidence of side effects in patients given no premedication
was higher than that in patients given premedication.
Dexmedetomidine is an α2-adrenergic agonist which
can be used with other intravenous anesthetic medications
in various surgical fields. The use of dexmedetomidine in
ECT may decrease hemodynamic responses (8-10).
Previous studies have shown that MAP and HR decreased
in patients to whom ECT was administered (5, 11, 12). The
results of the present study show similar results.
Anesthetic agents used in ECT are desirable as they
decrease the recovery period (13). The effect of
dexmedetomidine and midazolam on the recovery period
is controversial in the research literature. Some studies
have found that dexmedetomidine and midazolam increase
the recovery period (14); however, other studies have
found that they have no effect on the recovery period (4,
11). The present study found no significant difference in
terms of the recovery period between patients to whom
dexmedetomidine and midazolam were administered as
premedication and patients to whom no premedication was
administered.

premedication. A study by Loimer et al. (16) reported that
midazolam shortened the attack period. According to the
above-mentioned study by Mızrak et al. (4),
dexmedetomidine may increase the attack period by
allowing better convulsion activity than midazolam. The
results of this study found that the attack periods in
dexmedetomidine patients were longer than in midazolam
patients. However, this difference was not statistically
significant. This non-significant difference may have
resulted from the use of barbiturates, which are known to
decrease the attack activity when used as the induction
agents in ECT.
A statistically significant difference was found between
midazolam patients and non-premedication in terms of
SpO2 value at the 10th minute after the premedication.
This effect may have resulted from midazolam suppressing
the respiration center by decreasing oxygen consumption
and cerebral circulation, based on the medication dose (17).
Although side effects such as coughing, headache,
postictal delirium, bradycardia, or hypertension due either
to ECT or to the anesthetic agents used were observed in

Although the therapeutic action of ECT is not fully
understood, the attack period is one of the more significant
indicators related to the efficacy of the therapy (15). The

patients in a previous study, most of the patients had good
prognoses and recovered on their own (18). Decreasing
possible side effects that may occur in patients, and waking
patients up in a comfortable way, are the aims of
premedication administered before ECT (19). Mızrak et al.
(4) reported that 4 patients developed coughing, and 5
developed headaches among dexmedetomidine patients. 2

recommended convulsion period is 25 seconds for
effective ECT. Recent studies have reported that the
healing efficiency of convulsions that continue for less than

patients developed coughing and 6 developed headaches
among midazolam patients (4). In the present study, only
coughing and tearing occurred as side effects in

15 seconds is decreased (5). A study by Mızrak et al. (4)
found that the convulsion periods in patients to whom
dexmedetomidine was administered were longer than those
of patients who were administered either midazolam or no

premedication patients. In contrast, coughing, tearing,
urinary incontinence, sweating, shivering, and postictal
delirium occurred as side effects in patients given no
premedication.
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Conclusions
Midazolam or dexmedetomidine administered as
premedication before ECT may prevent acute
hemodynamic responses that may occur as a response to
this therapy. Therefore, premedication administration may
be beneficial in reducing the side effects that occur after
ECT without affecting either the convulsion or the
recovery periods.
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